摘要
目的比较国产注射用紫杉醇脂质体＋顺铂与紫杉醇＋顺铂治疗非小细胞肺癌的临床疗效和安全性。方法采用随机、对照的方法进行研究，非小细胞肺癌130例分为试验组和对照组两组，两组各65例。试验组给予注射用紫杉醇脂质体135mg／m2，第1天＋顺铂30mg／m2，第1、2、3天，每3周为1个周期；对照组给予注射用紫杉醇135mg／m2，第1天＋顺铂30mg/m2，第1、2、3天，每3周为1个周期。结果共有120例患者可评价疗效和不良反应，两组各60例。试验组总有效率62．7％，对照组总有效率50．0％，但差异无统计学意义（P〉0．05）。主要不良反应为血液学毒性，以白细胞减少最明显，但差异无统计学意义（P〉0．05）。其他非血液学毒性不良反应方面，皮疹、恶心呕吐和肌肉痛，试验组发生率低于对照组，差异有统计学意义（P〈0．05）。结论国产注射用紫杉醇脂质体联合顺铂治疗非小细胞肺癌和传统紫杉醇效果相当，但其溶媒所产生的皮疹、恶心呕吐和肌肉痛等不良反应较传统紫杉醇少。
Objective To analyze the effects and side effects of paclitaxel liposomal plus cisplatin formula on non -small cell lung cancer（NSCLC） , compared with traditional paelitaxel plus cisplatin. Methods One hundred and thirty cases of NSCLC were randomly divided into test group （65 cases） given paclitaxel liposomal at 135 mg/m2 each session, and control group（65 eases） given traditional paclitaxel at 135 mg/m2 each session. Both groups received these regimens combined with eisplatin at 30 mg/m2 d1,d2,d3/every cycle,every 3 weeks cycle. Results Of all the 130 cases,120 cases were eligi- ble for the analysis of side effects and the overall response rate. Sixty cases in each group. The overall response rate were 62.7% in the test group and 50.0% in the control group. There was no significant difference between the two groups （ P 〉 0. 05 ）. The main adverse reactions to the toxicity of hematology is the reducing of the white blood cell, but there was no significant difference between the two groups. Non- hematologic toxic side effects were rash, nausea and vomiting, muscle pain, the incidence was sig- nificantly lower in the test group than that in the control group （ P 〈 0. 05 ）. Conclusions Paclitaxel liposomal combined with cisplatin in the treatment of NSCLC, being similarily effective as paclitaxel, can significantly lower the incidence of rash, nausea and vomiting, muscle pain.
出处
《中国实用医刊》
2011年第7期60-62,共3页
Chinese Journal of Practical Medicine
关键词
紫杉醇脂质体
非小细胞肺癌
顺铂
Paclitaxel liposomal
Non -small cell lung cancer
Cisplatin
